Original Article
Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary
N Engl J Med 2009; 360:2719-2729June 25, 2009
- Abstract
Background
Granulosa-cell tumors (GCTs) are the most common type of malignant ovarian sex cord–stromal tumor (SCST). The pathogenesis of these tumors is unknown. Moreover, their histopathological diagnosis can be challenging, and there is no curative treatment beyond surgery.
Methods
We analyzed four adult-type GCTs using whole-transcriptome paired-end RNA sequencing. We identified putative GCT-specific mutations that were present in at least three of these samples but were absent from the transcriptomes of 11 epithelial ovarian tumors, published human genomes, and databases of single-nucleotide polymorphisms. We confirmed these variants by direct sequencing of complementary DNA and genomic DNA. We then analyzed additional tumors and matched normal genomic DNA, using a combination of direct sequencing, analyses of restriction-fragment–length polymorphisms, and TaqMan assays.
Results
All four index GCTs had a missense point mutation, 402C→G (C134W), in FOXL2, a gene encoding a transcription factor known to be critical for granulosa-cell development. The FOXL2 mutation was present in 86 of 89 additional adult-type GCTs (97%), in 3 of 14 thecomas (21%), and in 1 of 10 juvenile-type GCTs (10%). The mutation was absent in 49 SCSTs of other types and in 329 unrelated ovarian or breast tumors.
Conclusions
Whole-transcriptome sequencing of four GCTs identified a single, recurrent somatic mutation (402C→G) in FOXL2 that was present in almost all morphologically identified adult-type GCTs. Mutant FOXL2 is a potential driver in the pathogenesis of adult-type GCTs.
Media in This Article
Figure 1
Histopathological Features of a Granulosa-Cell Tumor (GCT).Figure 2
The FOXL2 402C→G Missense Mutation.Article Activity
- Article
Granulosa-cell tumors (GCTs) occur at a frequency of 1 per 100,000 persons and account for less than 5% of all ovarian cancers.1 For women with advanced-stage or recurrent disease, the effectiveness of traditional chemotherapy has been limited, indicating the need for more effective therapeutic approaches.2 For stage I and II disease, reported 5-year survival rates vary widely, from 55% to 95%, perhaps indicating inconsistent diagnostic criteria for GCTs.1 The histopathological features of these tumors (Figure 1Figure 1
Histopathological Features of a Granulosa-Cell Tumor (GCT).) can be mimicked by a variety of other neoplasms.3 The cause and molecular pathogenesis of GCTs are unknown.4-7 GCTs have morphologic and molecular features that are similar to those of normal granulosa cells, including the expression of follicle-stimulating hormone receptor and inhibin.8,9 Cytogenetic studies have shown that GCTs have greater genomic stability than the more common epithelial ovarian cancers.4,10
Methods for rapidly sequencing whole cancer genomes have recently been developed,11-14 and initial studies have suggested that hundreds of samples of any cancer type would have to be studied to derive clinically useful information.15 Because GCTs are genomically stable, we hypothesized that common, GCT-specific molecular abnormalities in the transcriptomes of GCTs could be discovered through the analysis of a small number of samples. We thus subjected four GCTs to whole-transcriptome paired-end RNA sequencing (also called RNA-seq) (see Glossary).
Methods
Patients and Samples
We selected 4 ovarian adult-type GCTs (1 primary and 3 recurrent tumors) obtained from index patients, along with 10 ovarian carcinomas and 1 cell line derived from a serous borderline tumor provided by the OvCaRe (Ovarian Cancer Research) frozen tumor bank. Patients provided written informed consent for research using these tumor samples before undergoing surgery, and the consent form acknowledged that a loss of confidentiality could occur through the use of samples for research. Separate approval from the hospital's institutional review board was obtained to permit the use of these samples for RNA-sequencing experiments.
For primary validation, we obtained 74 formalin-fixed, paraffin-embedded blocks of frozen samples from additional putative GCTs, along with 48 matched samples of normal tissue. We obtained two additional blocks (GCT78 and GCT59) that were recurrences of samples GCT29 and GCT76, respectively, which we also genotyped. In addition, we analyzed frozen tissue samples from 149 epithelial ovarian tumors and 180 breast carcinomas. We obtained another series of formalin-fixed, paraffin-embedded ovarian sex cord–stromal tumors (SCSTs), some of which have been described previously16 (see Glossary). This second series consisted of 95 tumor samples: 27 adult-type GCTs, 8 juvenile-type GCTs, 23 fibromas, 14 Sertoli–Leydig cell tumors, 13 thecomas, and 10 steroid-cell tumors. (Details regarding the numbers and types of GCTs that were provided by each institution are listed in Table 1 in the Supplementary Appendix, available with the full text of this article at NEJM.org.)
Pathological Review
All tumor samples that are included in this study were independently reviewed by a gynecologic pathologist before mutational analysis. In cases in which the review diagnosis differed from the source diagnosis, the samples were further reviewed by another gynecologic pathologist, who acted as arbiter. Both pathologists were unaware of the results of genomics studies. Immunohistochemical staining for calretinin, epithelial membrane antigen, and inhibin were performed. (For details, see the Methods section in the Supplementary Appendix.) Histologic images of all GCTs were obtained with the use of a ScanScope XT digital scanning system (Aperio Technologies) and are available on request.
Paired-End RNA Sequencing and Analysis
A detailed description of RNA sequencing and subsequent data analysis are provided in the Methods section of the Supplementary Appendix. Briefly, double-stranded complementary DNA (cDNA) was synthesized from polyadenylated RNA and sheared. The fraction from 190 to 210 bp was isolated and amplified with 10 cycles of a polymerase-chain-reaction (PCR) assay, according to the paired-end protocol for the Genome Analyzer II (GAII) (Illumina). The resulting libraries were then sequenced on the GAII. Short DNA sequences (reads) obtained from the GAII were mapped to the reference human genome (National Center for Biotechnology Information build 36.1, hg18) and a database of known exon junctions13 with the use of MAQ software17 in paired-end mode. Putative point mutations and small insertions and deletions were identified (for details, see the Methods section in the Supplementary Appendix). These mutations were cross-referenced against human genome databases to eliminate previously described germ-line variants. Genome instability of the index samples was determined with the use of Affymetrix 6.0 genotyping arrays interpreted for copy number.
Mutation Validation
We selected variants present in at least three of the four GCT RNA-sequencing libraries and examined RNA-sequencing libraries from 10 non-GCT ovarian tumors and from a serous borderline-tumor–derived cell line for the presence of the GCT-derived variants. Transcriptome variants that were absent in the 11 non-GCT ovarian tumors were classified as GCT-specific variants and subjected to further analysis. We confirmed the identification of the GCT-specific variants using Sanger sequencing of PCR amplicons of cDNA and genomic DNA (gDNA) obtained from the index samples (both tumor and matched normal tissue when available).
We used a combination of direct sequencing, analyses of restriction-fragment–length polymorphisms (RFLPs), and a TaqMan real-time PCR–based allelic discrimination assay (Applied Biosystems) to genotype the FOXL2 402C→G mutation in additional cancers (see Glossary). In the primary validation studies, samples were scored as positive or negative for this mutation only if there were clear and concordant results from at least two assays. The use of assays with different primers was intended to minimize PCR artifacts caused by amplifying poor-quality DNA templates from formalin-fixed, paraffin-embedded tissue blocks.18 The TaqMan and RFLP assays produced clear and concordant results for all 149 non-GCT tumors, as well as for the 4 index GCT samples, and these results matched the results from sequencing of the 74 samples with interpretable results from all assays. In cases in which the PCR–RFLP analysis did not produce a PCR product of sufficient quality and quantity for further analysis (presumably because of poor-quality template DNA), it was replaced by the TaqMan assay, which was also used in primary screening for the additional series of SCSTs studied to determine the frequency of mutations in related tumors.
Results
Paired-End Whole-Transcriptome RNA Sequencing
The genomic stability of the four index GCTs was confirmed by inferring DNA copy-number alterations from high-density genotyping arrays (Fig. 1 in the Supplementary Appendix). The samples were then subjected to RNA sequencing. The total number of mapped DNA sequence reads and the total number of reads (which included the fraction of exonic, intronic, and intergenic sequences), the number of base pairs covered, and details regarding the variants detected in the 4 GCT samples and in the other 11 ovarian neoplasm-derived comparator libraries are shown in Table 1Table 1
Summary of Data Generation from Whole-Transcriptome Paired-End RNA Sequencing.. Sequence reads from these samples showed expected subtype-specific differential gene expression (Fig. 2 in the Supplementary Appendix).Validation of Implicated Variants
The RNA-sequencing analysis generates short reads that map to a reference sequence. Figure 2Figure 2
The FOXL2 402C→G Missense Mutation. depicts typical RNA-sequencing data for a portion of the FOXL2 gene and shows how nucleotides for expressed genes can be represented by multiple reads, as opposed to an average read generated by standard sequencing. We predicted the identification of mutations using SNVmix, a probabilistic model that is used to infer such a result on the basis of a binomial mixture model (see the Supplementary Appendix for details). Two putative point mutations that were implicated by SNVmix and a base-pair insertion met our criteria for candidate tumorigenic mutations, since they were present in three or more GCTs and absent in the comparator sequence libraries (i.e., sequence libraries generated from non-GCT tumors, in addition to sequences in existing data banks). All four GCTs contained a C→G change in the FOXL2 gene at position 402 (genomic position 140147853 on chromosome 3; National Center for Biotechnology Information [NCBI] human genome build 36.1), which is predicted to result in the substitution of a tryptophan residue for a highly conserved cysteine residue at amino acid position 134 (C134W) (Figure 2). The Grantham distance (see Glossary) of this amino acid change was 215, the highest value we observed in the 6410 nonsynonymous predicted variants derived from the analysis of all 15 ovarian cancers (Table 1). Of the 6410 mutations, only 15 had a Grantham distance of 215. All predicted variants from the four index GCTs are available from the European Genotyping Archive (accession number, EGA00000000040).Using two additional independent methods, we validated the FOXL2 402C→G variant in the cDNA and gDNA of the four index samples and determined that it was somatic in the two samples from patients for whom normal tissue was available. The two other variants that met our criteria were one at genomic position 357452 on chromosome 4 in ZNF141 and a base-pair insertion at position 24488600 on chromosome 16 in RBBP6. We could not confirm either of these variants by PCR validation and considered them to be systematic artifacts generated by misalignment of the reads. We therefore focused on the FOXL2 402C→G variant (Figure 3AFigure 3
Discovery and Validation of the FOXL2 402C→G Missense Mutation., and Fig. 3 in the Supplementary Appendix).Prevalence of FOXL2 402C→G
We used a combination of RFLP, TaqMan (Figure 4AFigure 4
Results of TaqMan Assay, Direct Sequencing, and Immunohistochemical Analysis.), and direct-sequencing (Figure 4B) analyses to determine whether the FOXL2 variant was present in 69 samples of pathologically confirmed GCTs (67 adult-type and 2 juvenile-type GCTs) and three other SCSTs (Figure 3B). We obtained unequivocal results in 64 of 69 GCTs and in all 3 SCSTs (Fig. 4 in the Supplementary Appendix). FOXL2 402C→G was present in 59 of 64 GCTs. Two additional paired recurrences also carried the 402C→G variant. The mutation was absent in DNA extracted from paired normal tissue from 48 mutation-positive patients. Five GCTs were mutation-negative, including the two juvenile-type GCTs (GCT24 and GCT45) (Fig. 5A and 5B in the Supplementary Appendix). Two mutation-negative tumors (GCT11 and GCT22) did not express inhibin or calretinin, which were expressed in 100% and 86% of the mutation-positive GCTs, respectively (Fig. 5C and 5D in the Supplementary Appendix). The fifth mutation-negative tumor (GCT33) had a prominent fibrothecomatous component, also seen in two mutation-positive samples (GCT44 and GCT71) (Fig. 5E in the Supplementary Appendix). The FOXL2 mutation was absent in 149 other epithelial ovarian tumors and in 180 breast cancers (Figure 3D).Sample GCT18, a thecoma, was the only non-GCT tumor that was positive for the FOXL2 variant in the first validation series. Further analysis of this sample revealed a minor granulosa-cell component (Fig. 6 in the Supplementary Appendix). Three tumors (GCT9, GCT35, and GCT38) were either homozygous for the 402C→G (C134W) mutation, as determined by sequencing and the TaqMan assay profile, or had a loss of heterozygosity of the normal allele. A single GCT (GCT44) had both the 402C→G (C134W) mutation and a second FOXL2 somatic variant, 404A→G (E135G) (Fig. 7 in the Supplementary Appendix). By sequencing cloned PCR products, we observed that these variants were in cis. This sample tested positive for the 402C→G variant on RFLP analysis, but repeated TaqMan assays did not produce results. We did not detect the 404A→G variant in any of the 4 index samples, in 37 other GCTs, or in 21 non-GCTs for which we had sequencing data.
We carried out fluorescence in situ hybridization to assess potential amplification of FOXL2 on 32 GCTs and 5 epithelial ovarian cancers and obtained negative results (Fig. 8 and Table 2 in the Supplementary Appendix). Immunohistochemical analysis showed that FOXL2 was expressed in the nuclei of normal granulosa cells as well as in GCTs that were heterozygous or appeared to be hemizygous or homozygous for the 402C→G mutation (Figure 4C, 4D, and 4E).
Test for Replication
We obtained a second series of 95 clinical samples to determine the specificity of this variant within SCSTs of the ovary (Figure 3C). We found the FOXL2 mutation in all 27 adult-type GCTs that we tested. Among the other ovarian SCSTs, 1 of 8 juvenile-type GCTs and 2 of 13 thecomas carried the FOXL2 variant; all other tumors (14 Sertoli–Leydig cell tumors, 23 fibromas, and 10 steroid-cell tumors) were negative for the mutation.
Discussion
We found a recurrent somatic mutation (402C→G) in FOXL2 in tumor samples from four patients with GCTs, using RNA sequencing to study the transcriptomes of the samples. FOXL2 was not expressed in the other RNA-sequencing libraries derived from ovarian cancers, and the mutation was absent in the gDNA of these cancers. We analyzed two additional series of GCTs for this mutation. The combined results from both series showed that the mutation was present in 86 of 89 morphologically identified adult-type GCTs (97%), in 1 of 10 juvenile-type GCTs (10%), and in 3 of 14 thecomas (21%); the mutation was absent in 49 other ovarian SCSTs, in 149 epithelial ovarian tumors, and in 180 breast cancers.
Although juvenile-type GCTs share some features with adult-type GCTs and have a similar biomarker-expression profile, they differ with respect to clinical presentation (in prepubertal children vs. young adults) and histopathological features.1 These features, along with those of a naturally occurring mouse model of juvenile-type GCT,20 suggest that juvenile-type GCT is a distinct disease from the adult type; our data support this hypothesis. The finding of a mutation that is characteristic of adult-type GCTs in thecomas is not surprising because the distinction between thecomas and GCTs can be arbitrary and mixtures of the two types of tumor cells may be seen in individual tumors. The diagnostic category of granulosa–theca-cell tumor has been used for such cases in the past.21 The presence of the FOXL2 mutation in a subgroup of thecomas suggests a cut point on this morphologic continuum between thecoma and GCT. Studies of additional patients with follow-up will be required to determine whether thecomas with a FOXL2 mutation are biologically more similar to GCTs than to mutation-negative thecomas.
The three mutation-negative adult-type GCTs were diagnostically challenging. Two of these tumors had immunohistochemical profiles that were distinct from those of most GCTs, suggesting that they were not true GCTs but, rather, morphologic mimics. We selected GCTs for this study on the basis of light microscopy (reflecting current diagnostic practice), not on the basis of immunostaining profiles; had we taken immunostaining into consideration, we would have excluded these two tumors.
FOXL2 is a member of the forkhead–winged-helix family of transcription factors containing a highly conserved DNA-binding forkhead domain. It is one of the earliest markers of ovarian differentiation, and its expression persists into adulthood. FOXL2 is required for the normal development of granulosa cells22,23 and shows strong expression in granulosa cells and moderate expression in stromal cells; no expression has been detected in oocytes.22,24 Few targets of FOXL2 have been described; it has been shown to have a role, as part of an AP1–SMAD3–SMAD4 complex, in activating the transcription of GNRHR (encoding the gonadotropin-releasing hormone receptor) in pituitary cells and repressing the transcription of STAR (encoding steroidogenic acute regulatory protein) in the adult ovary.25,26 Granulosa-cell proliferation and differentiation are governed, at least in part, by transforming growth factor β–receptor signaling through SMAD2 and SMAD3.26
To date, all mutations that have been described in FOXL2 are germ-line loss-of-function mutations and are associated with the blepharophimosis–ptosis–epicanthus inversus syndrome27,28 with primary ovarian failure (in particular, granulosa-cell failure29). Like JAK2 mutations in the case of polycythemia vera,30 mutations in FOXL2 are present in a large majority of adult-type granulosa-cell tumors and involve a single base substitution. Cys 134 is located on the surface of the forkhead DNA-binding domain; modeling suggests that the substitution of tryptophan for cysteine does not disrupt the folding of this domain or its interactions with DNA (Fig. 9 in the Supplementary Appendix). We therefore speculate that its pathogenicity is imparted through other mechanisms, such as the altering of one or more interactions between FOXL2 and other proteins. We have ruled out mislocalization of the mutant protein as a probable cause of its pathogenicity by showing that FOXL2 is present in the nuclei of GCTs (Figure 4) that are either heterozygous or appear to be hemizygous or homozygous for the 402C→G mutation (Table 2 in the Supplementary Appendix).
Next-generation sequencing has been used to characterize mutations and gene expression in cell lines and to identify mutations in patients with acute myeloid leukemia.12,13,31 On the basis of these studies and others, it has been suggested that the genomic complexity of cancers is so extreme that whole-genome–sequencing studies must be performed at great depth and must include several hundred cancers of any type to yield data that can be interpreted clinically or biologically.11,14,15 However, our data suggest that for some tumors (most likely the cytogenetically simple and clinicopathologically homogeneous ones, such as GCTs), the pattern of somatic mutations is recurrent and constrained and thus can be analyzed by studying a small number of samples. Since transcriptomes are less complex and 50 to 100 times smaller than genomes, sequencing transcriptomes, as opposed to genomes, has been proposed as a more efficient method of finding mutations expressed through RNA.12 Our study supports this proposal. This approach cannot detect certain types of mutations, such as noncoding changes and mutations that are subject to nonsense-mediated decay.
The diagnosis of GCTs can be difficult, and treatment for this cancer is nonspecific and often unsuccessful. We speculate that testing for the presence of the FOXL2 402C→G mutation may improve diagnosis in problematic cases and lead to more targeted therapies. In addition, new insights into the cause of this disease may be derived from future studies of the function of this mutation.
Supported by grants from the British Columbia Cancer Foundation and the Vancouver General Hospital Foundation (to OvCaRe in British Columbia), Genome Canada (to the Genome Sciences Centre), the Michael Smith Foundation for Health Research (to OvCaRe and the Genome Sciences Centre and to Drs. Shah, Marra, and Huntsman), Eli Lilly Canada (to Dr. Köbel), and the Canadian Institutes of Health Research's Training Program on Clinician-Scientists in Molecular Oncologic Pathology (to Dr. Turashvili); nondirected research funds from Sanofi-Aventis (to the Genetic Pathology Evaluation Centre); and funding for a Canada Research Chair in Molecular Oncology (to Dr. Aparicio). The contributing tumor banks were supported by OvCaRe and Ovarian Cancer Canada (Vancouver General Hospital), Fonds de la Recherche en Santé du Québec (Montreal), and Ovarian Cancer Canada (Ottawa). The Westmead Gynaecological Oncology Tissue Bank is a member of the Australasian Biospecimens Network-Oncology group, which is funded by the Australian National Health and Medical Research Council; by Cancer Research UK, the University of Cambridge, Hutchinson Whampoa, the Experimental Cancer Medicine Centre, and the National Institute for Health Research's Cambridge Biomedical Research Centre; by a grant (DAMD17-01-1-0729) from the U.S. Army Medical Research and Materiel Command; and by grants from the Cancer Council Tasmania, the Cancer Foundation of Western Australia, and the National Health and Medical Research Council of Australia to the Australian Ovarian Cancer Study.
Dr. Köbel reports receiving grant support from Eli Lilly; and Dr. Huntsman, receiving grant support from Sanofi-Aventis and Novartis and being listed as an inventor on a provisional patent application filed by the British Columbia Cancer Agency on the diagnostic use of the FOXL2 402C→G mutation and its development as a therapeutic target. No other potential conflict of interest relevant to this article was reported.
This article (10.1056/NEJMoa0902542) was published on June 10, 2009, at NEJM.org.
We thank Ying Ng and Katie Chow for performing the array comparative-genomic-hybridization experiments; Krista Marcon for performing the immunohistochemical analysis and preparing tissue sections for DNA extraction; Samuel Leung for establishing the online image archive; Mona Mazgani and Salvador Saldivar for helping in the acquisition of informed consent and specimens for the gynecologic tumor bank at Vancouver General Hospital; Catherine Kennedy for helping in the acquisition of specimens from the Westmead Gynaecological Oncology Tissue Bank; Julie Irving for helping with accessing specimens for the secondary validation; the members of the Australian Ovarian Cancer Study (AOCS) management group: D. Bowtell, G. Chenevix-Trench, A. Green, P. Webb, A. deFazio, and D. Gertig; the AOCS study nurses and research assistants; and all the patients who participated in the AOCS study.
Source Information
The authors' affiliations are listed in the Appendix.
Address reprint requests to Dr. Huntsman at the Center for Translational and Applied Genomics, British Columbia Cancer Agency, 600 W. 10th Ave., Vancouver, BC V5Z 4E6, Canada, or at dhuntsma@bccancer.bc.ca.
Appendix
The authors' affiliations are as follows: the Centre for Translational and Applied Genomics (S.P.S., J.S., K.C.W., G.L., A.Z., S.E.K., M.S., R.G., E.Y., N.B., D.G.H.), the Genetic Pathology Evaluation Centre (M.K., E.M., P.B.C., C.B.G., D.G.H.), the Genome Sciences Centre (R.D.M., S.J., R.V., Y.Z., T.Z., M.H., M.M.), the Cheryl Brown Ovarian Cancer Outcomes Unit (K.D.S.), the Department of Gynecology (D.M.), and the Department of Molecular Oncology (J.K., G.T., S.A.A.), British Columbia Cancer Agency; Vancouver General Hospital (M.K., E.M., P.B.C., D.M., C.B.G., D.G.H.); and the University of British Columbia (M.K., E.M., P.B.C., P.L., C.B.G., D.G.H.) — all in Vancouver; the Department of Pathology, University of Toronto and University Health Network, Toronto (B.A.C.); the Departments of Pathology and Laboratory Medicine (C.C.) and Cellular and Molecular Medicine (B.V.), University of Ottawa, Ottawa; the Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal (J.M., D.P., A.-M.M.-M.); and the Department of Biochemistry, University of Alberta, Edmonton (J.N.M.G.) — all in Canada; the Department of Gynaecological Oncology, Westmead Hospital and Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead (A.D., D.D.L.B.); Peter MacCallum Cancer Centre, Melbourne (D.D.L.B.); Queensland Institute for Medical Research, Brisbane (D.D.L.B.); and Victorian Cervical Cytology Registry, Melbourne (D.D.L.B.) — all in Australia; the Department of Pathology, Magee–Women's Hospital, University of Pittsburgh Medical Center, Pittsburgh (C.Z.); and the Functional Genomics of Ovarian Cancer Laboratory, Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Cambridge, United Kingdom (C.A.P., M.J.-L., J.D.B.).
- References
References
1
Schumer ST ,Cannistra SA . Granulosa cell tumor of the ovary. J Clin Oncol 2003;21:1180-1189
CrossRef | Web of Science | Medline2
Colombo N ,Parma G ,Zanagnolo V ,Insinga A . Management of ovarian stromal cell tumors. J Clin Oncol 2007;25:2944-2951
CrossRef | Web of Science | Medline3
Young RH . Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems. Mod Pathol 2005;18:Suppl 2:S81-S98
CrossRef | Web of Science | Medline4
Mayr D ,Hirschmann A ,Marlow S ,Horvath C ,Diebold J . Analysis of selected oncogenes (AKT1, FOS, BCL2L2, TGFbeta) on chromosome 14 in granulosa cell tumors (GCTs): a comprehensive study on 30 GCTs combining comparative genomic hybridization (CGH) and fluorescence-in situ-hybridization (FISH). Pathol Res Pract 2008;204:823-830
CrossRef | Web of Science | Medline5
Kappes S ,Milde-Langosch K ,Kressin P , et al. p53 Mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry. Int J Cancer 1995;64:52-59
CrossRef | Web of Science | Medline6
Liu FS ,Ho ES ,Lai CR , et al. Overexpression of p53 is not a feature of ovarian granulosa cell tumors. Gynecol Oncol 1996;61:50-53
CrossRef | Web of Science | Medline7
King LA ,Okagaki T ,Gallup DG ,Twiggs LB ,Messing MJ ,Carson LF . Mitotic count, nuclear atypia, and immunohistochemical determination of Ki-67, c-myc, p21-ras, c-erbB2, and p53 expression in granulosa cell tumors of the ovary: mitotic count and Ki-67 are indicators of poor prognosis. Gynecol Oncol 1996;61:227-232
CrossRef | Web of Science | Medline8
Fuller PJ ,Chu S . Signalling pathways in the molecular pathogenesis of ovarian granulosa cell tumours. Trends Endocrinol Metab 2004;15:122-128
CrossRef | Web of Science | Medline9
Ligtenberg MJ ,Siers M ,Themmen AP ,Hanselaar TG ,Willemsen W ,Brunner HG . Analysis of mutations in genes of the follicle-stimulating hormone receptor signaling pathway in ovarian granulosa cell tumors. J Clin Endocrinol Metab 1999;84:2233-2234
CrossRef | Web of Science | Medline10
Fletcher JA ,Gibas Z ,Donovan K , et al. Ovarian granulosa-stromal cell tumors are characterized by trisomy 12. Am J Pathol 1991;138:515-520
Web of Science | Medline11
Leary RJ ,Lin JC ,Cummins J , et al. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A 2008;105:16224-16229
CrossRef | Web of Science | Medline12
Ley TJ ,Mardis ER ,Ding L , et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008;456:66-72
CrossRef | Web of Science | Medline13
Morin R ,Bainbridge M ,Fejes A , et al. Profiling the HeLa S3 transcriptome using randomly primed cDNA and massively parallel short-read sequencing. Biotechniques 2008;45:81-94
CrossRef | Web of Science | Medline14
Parsons DW ,Jones S ,Zhang X , et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-1812
CrossRef | Web of Science | Medline15
Stratton MR ,Campbell PJ ,Futreal PA . The cancer genome. Nature 2009;458:719-724
CrossRef | Web of Science | Medline16
Zhao C ,Vinh TN ,McManus K ,Dabbs D ,Barner R ,Vang R . Identification of the most sensitive and robust immunohistochemical markers in different categories of ovarian sex cord-stromal tumors. Am J Surg Pathol 2009;33:354-366
CrossRef | Web of Science | Medline17
Li H ,Ruan J ,Durbin R . Mapping short DNA sequencing reads and calling variants using mapping quality scores. Genome Res 2008;18:1851-1858
CrossRef | Web of Science | Medline18
Qiu W ,Hu M ,Sridhar A , et al. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet 2008;40:650-655
CrossRef | Web of Science | Medline19
Crooks GE ,Hon G ,Chandonia JM ,Brenner SE . WebLogo: a sequence logo generator. Genome Res 2004;14:1188-1190
CrossRef | Web of Science | Medline20
Dorward AM ,Shultz KL ,Horton LG ,Li R ,Churchill GA ,Beamer WG . Distal Chr 4 harbors a genetic locus (Gct1) fundamental for spontaneous ovarian granulosa cell tumorigenesis in a mouse model. Cancer Res 2005;65:1259-1264
CrossRef | Web of Science | Medline21
Fletcher CDM. Diagnostic histopathology of tumors. London: Churchill Livingstone, 1995.
22
Cocquet J ,Pailhoux E ,Jaubert F , et al. Evolution and expression of FOXL2. J Med Genet 2002;39:916-921
CrossRef | Web of Science | Medline23
Schmidt D ,Ovitt CE ,Anlag K , et al. The murine winged-helix transcription factor Foxl2 is required for granulosa cell differentiation and ovary maintenance. Development 2004;131:933-942
CrossRef | Web of Science | Medline24
Pannetier M ,Fabre S ,Batista F , et al. FOXL2 activates P450 aromatase gene transcription: towards a better characterization of the early steps of mammalian ovarian development. J Mol Endocrinol 2006;36:399-413
CrossRef | Web of Science | Medline25
Ellsworth BS ,Burns AT ,Escudero KW ,Duval DL ,Nelson SE ,Clay CM . The gonadotropin releasing hormone (GnRH) receptor activating sequence (GRAS) is a composite regulatory element that interacts with multiple classes of transcription factors including Smads, AP-1 and a forkhead DNA binding protein. Mol Cell Endocrinol 2003;206:93-111
CrossRef | Web of Science | Medline26
Pisarska MD ,Bae J ,Klein C ,Hsueh AJ . Forkhead L2 is expressed in the ovary and represses the promoter activity of the steroidogenic acute regulatory gene. Endocrinology 2004;145:3424-3433
CrossRef | Web of Science | Medline27
Crisponi L ,Deiana M ,Loi A , et al. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome. Nat Genet 2001;27:159-166
CrossRef | Web of Science | Medline28
De Baere E ,Dixon MJ ,Small KW , et al. Spectrum of FOXL2 gene mutations in blepharophimosis-ptosis-epicanthus inversus (BPES) families demonstrates a genotype-phenotype correlation. Hum Mol Genet 2001;10:1591-1600
CrossRef | Web of Science | Medline29
Beysen D ,Vandesompele J ,Messiaen L ,De Paepe A ,De Baere E . The human FOXL2 mutation database. Hum Mutat 2004;24:189-193
CrossRef | Web of Science | Medline30
Kralovics R ,Passamonti F ,Buser AS , et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790
Full Text | Web of Science | Medline31
Campbell PJ ,Stephens PJ ,Pleasance ED , et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet 2008;40:722-729
CrossRef | Web of Science | Medline
- Citing Articles (68)
Citing Articles
1
Clinton K. Matson, David Zarkower. (2012) Sex and the singular DM domain: insights into sexual regulation, evolution and plasticity. Nature Reviews Genetics
CrossRef2
Richard Oparka, Andrew Cassidy, Stephanie Reilly, Alasdair Stenhouse, W Glenn McCluggage, C Simon Herrington. (2012) The C134W (402 C>G) FOXL2 mutation is absent in ovarian gynandroblastoma: insights into the genesis of an unusual tumour. Histopathologyno-no
CrossRef3
Louise M. Bilezikjian, Nicholas J. Justice, Alissa N. Blackler, Ezra Wiater, Wylie W. Vale. (2012) Cell-Type Specific Modulation of Pituitary Cells by Activin, Inhibin and Follistatin. Molecular and Cellular Endocrinology
CrossRef4
Heravi-Moussavi, Alireza, Anglesio, Michael S., Cheng, S.-W. Grace, Senz, Janine, Yang, Winnie, Prentice, Leah, Fejes, Anthony P., Chow, Christine, Tone, Alicia, Kalloger, Steve E., Hamel, Nancy, Roth, Andrew, Ha, Gavin, Wan, Adrian N.C., Maines-Bandiera, Sarah, Salamanca, Clara, Pasini, Barbara, Clarke, Blaise A., Lee, Anna F., Lee, Cheng-Han, Zhao, Chengquan, Young, Robert H., Aparicio, Samuel A., Sorensen, Poul H.B., Woo, Michelle M.M., Boyd, Niki, Jones, Steven J.M., Hirst, Martin, Marra, Marco A., Gilks, Blake, Shah, Sohrab P., Foulkes, William D., Morin, Gregg B., Huntsman, David G., . (2012) Recurrent Somatic DICER1 Mutations in Nonepithelial Ovarian Cancers. New England Journal of Medicine 366:3, 234-242
Full Text5
C.-H. Lee, W.-B. Ou, A. Marino-Enriquez, M. Zhu, M. Mayeda, Y. Wang, X. Guo, A. L. Brunner, F. Amant, C. A. French, R. B. West, J. N. McAlpine, C. B. Gilks, M. B. Yaffe, L. M. Prentice, A. McPherson, S. J. M. Jones, M. A. Marra, S. P. Shah, M. van de Rijn, D. G. Huntsman, P. Dal Cin, M. Debiec-Rychter, M. R. Nucci, J. A. Fletcher. (2012) 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proceedings of the National Academy of Sciences 109:3, 929-934
CrossRef6
J. Ding, A. Bashashati, A. Roth, A. Oloumi, K. Tse, T. Zeng, G. Haffari, M. Hirst, M. A. Marra, A. Condon, S. Aparicio, S. P. Shah. (2012) Feature-based classifiers for somatic mutation detection in tumour-normal paired sequencing data. Bioinformatics 28:2, 167-175
CrossRef7
K. Shiroguchi, T. Z. Jia, P. A. Sims, X. S. Xie. (2012) Digital RNA sequencing minimizes sequence-dependent bias and amplification noise with optimized single-molecule barcodes. Proceedings of the National Academy of Sciences
CrossRef8
David M Berman, Marcus W Bosenberg, Robin L Orwant, Beth L Thurberg, Gulio F Draetta, Christopher DM Fletcher, Massimo Loda. (2012) Investigative pathology: leading the post-genomic revolution. Laboratory Investigation 92:1, 4-8
CrossRef9
Sietske T Bakker, Henri J van de Vrugt, Jenny A Visser, Elly Delzenne-Goette, Anja van der Wal, Mariska AD Berns, Marieke van de Ven, Anneke B Oostra, Sandra de Vries, Piet Kramer, Fré Arwert, Martin van der Valk, Johan P de Winter, Hein te Riele. (2012) Fancf-deficient mice are prone to develop ovarian tumours. The Journal of Pathology 226:1, 28-39
CrossRef10
Stephen Yip, Yaron S Butterfield, Olena Morozova, Suganthi Chittaranjan, Michael D Blough, Jianghong An, Inanc Birol, Charles Chesnelong, Readman Chiu, Eric Chuah, Richard Corbett, Rod Docking, Marlo Firme, Martin Hirst, Shaun Jackman, Aly Karsan, Haiyan Li, David N Louis, Alexandra Maslova, Richard Moore, Annie Moradian, Karen L Mungall, Marco Perizzolo, Jenny Qian, Gloria Roldan, Eric E Smith, Jessica Tamura-Wells, Nina Thiessen, Richard Varhol, Samuel Weiss, Wei Wu, Sean Young, Yongjun Zhao, Andrew J Mungall, Steven JM Jones, Gregg B Morin, Jennifer A Chan, J Gregory Cairncross, Marco A Marra. (2012) Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. The Journal of Pathology 226:1, 7-16
CrossRef11
D. E. Larson, C. C. Harris, K. Chen, D. C. Koboldt, T. E. Abbott, D. J. Dooling, T. J. Ley, E. R. Mardis, R. K. Wilson, L. Ding. (2011) SomaticSniper: Identification of Somatic Point Mutations in Whole Genome Sequencing Data. Bioinformatics
CrossRef12
Francesco Raspagliesi, Fabio Martinelli, Barbara Grijuela, Valentina Guadalupi. (2011) Third-line chemotherapy with tyrosine kinase inhibitor (imatinib mesylate) in recurrent ovarian granulosa cell tumor: Case report. Journal of Obstetrics and Gynaecology Research 37:12, 1864-1867
CrossRef13
Katherine B. Geiersbach, Elke A. Jarboe, Mona S. Jahromi, Christine L. Baker, Christian N. Paxton, Sheryl R. Tripp, Joshua D. Schiffman. (2011) FOXL2 mutation and large-scale genomic imbalances in adult granulosa cell tumors of the ovary. Cancer Genetics 204:11, 596-602
CrossRef14
Mikko Anttonen, Anniina Färkkilä, Hanna Tauriala, Marjut Kauppinen, David T MacLaughlin, Leila Unkila-Kallio, Ralf Bützow, Markku Heikinheimo. (2011) Anti-Müllerian hormone inhibits growth of AMH type II receptor-positive human ovarian granulosa cell tumor cells by activating apoptosis. Laboratory Investigation 91:11, 1605-1614
CrossRef15
Emanuela D'Angelo, Ana Mozos, Daiei Nakayama, Iñigo Espinosa, Lluis Catasus, Josefina Muñoz, Jaime Prat. (2011) Prognostic significance of FOXL2 mutation and mRNA expression in adult and juvenile granulosa cell tumors of the ovary. Modern Pathology 24:10, 1360-1367
CrossRef16
Linda E Kelemen, Martin Köbel. (2011) Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. The Lancet Oncology 12:11, 1071-1080
CrossRef17
Daichi Maeda, Junji Shibahara, Takahiko Sakuma, Masanori Isobe, Shinichi Teshima, Masaya Mori, Katsutoshi Oda, Shunsuke Nakagawa, Yuji Taketani, Shumpei Ishikawa, Masashi Fukayama. (2011) β-catenin (CTNNB1) S33C Mutation in Ovarian Microcystic Stromal Tumors. The American Journal of Surgical Pathology 35:10, 1429-1440
CrossRef18
N. H. Uhlenhaut, M. Treier. (2011) Forkhead transcription factors in ovarian function. Reproduction 142:4, 489-495
CrossRef19
Sebastian Vaughan, Jermaine I. Coward, Robert C. Bast, Andy Berchuck, Jonathan S. Berek, James D. Brenton, George Coukos, Christopher C. Crum, Ronny Drapkin, Dariush Etemadmoghadam, Michael Friedlander, Hani Gabra, Stan B. Kaye, Chris J. Lord, Ernst Lengyel, Douglas A. Levine, Iain A. McNeish, Usha Menon, Gordon B. Mills, Kenneth P. Nephew, Amit M. Oza, Anil K. Sood, Euan A. Stronach, Henning Walczak, David D. Bowtell, Frances R. Balkwill. (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews Cancer 11:10, 719-725
CrossRef20
Rebecca Buell-Gutbrod, Marina Ivanovic, Anthony Montag, Ernst Lengyel, Oluwole Fadare, Katja Gwin. (2011) FOXL2 and SOX9 Distinguish the Lineage of the Sex Cord–Stromal Cells in Gonadoblastomas. Pediatric and Developmental Pathology 14:5, 391-395
CrossRef21
Rotem Gershon, Sarit Aviel-Ronen, Jacob Korach, Vered Daniel-Carmi, Camila Avivi, Dalia Bar-Ilan, Iris Barshack, Dror Meirow, Gilad Ben-Baruch, Yoram Cohen. (2011) FOXL2 C402G mutation detection using MALDI-TOF-MS in DNA extracted from Israeli granulosa cell tumors. Gynecologic Oncology 122:3, 580-584
CrossRef22
A.-L. Todeschini, A. Dipietromaria, D. L'Hote, F. Z. Boucham, A. B. Georges, P. J. E. Pandaranayaka, S. Krishnaswamy, I. Rivals, C. Bazin, R. A. Veitia. (2011) Mutational probing of the forkhead domain of the transcription factor FOXL2 provides insights into the pathogenicity of naturally occurring mutations. Human Molecular Genetics 20:17, 3376-3385
CrossRef23
V. E. Velculescu, L. A. Diaz. (2011) Understanding the Enemy. Science Translational Medicine 3:98, 98ps37-98ps37
CrossRef24
J S Richards, H-Y Fan, Z Liu, M Tsoi, M-N Laguë, A Boyer, D Boerboom. (2011) Either Kras activation or Pten loss similarly enhance the dominant-stable CTNNB1-induced genetic program to promote granulosa cell tumor development in the ovary and testis. Oncogene
CrossRef25
M. Mannstadt, E. Holick, W. Zhao, H. Juppner. (2011) Mutational analysis of GCMB, a parathyroid-specific transcription factor, in parathyroid adenoma of primary hyperparathyroidism. Journal of Endocrinology 210:2, 165-171
CrossRef26
Sandrine Caburet, Adrien Georges, David L’Hôte, Anne-Laure Todeschini, Bérénice A. Benayoun, Reiner A. Veitia. (2011) The transcription factor FOXL2: At the crossroads of ovarian physiology and pathology. Molecular and Cellular Endocrinology
CrossRef27
Katayoon Kasaian, Steven JM Jones. (2011) A new frontier in personalized cancer therapy: mapping molecular changes. Future Oncology 7:7, 873-894
CrossRef28
Margherita Nannini, Guido Biasco, Alessandra Maleddu, Maria A Pantaleo. (2011) New molecular targets beyond KIT and PDGFRA in gastrointestinal stromal tumors: present and future. Expert Opinion on Therapeutic Targets 15:7, 803-815
CrossRef29
Stephanie A. Pangas. (2011) Bone morphogenetic protein signaling transcription factor (SMAD) function in granulosa cells. Molecular and Cellular Endocrinology
CrossRef30
Maria Alexiadis, Natalie Eriksson, Stacey Jamieson, Melissa Davis, Ann E. Drummond, Simon Chu, Colin D. Clyne, George E. Muscat, Peter J. Fuller. (2011) Nuclear Receptor Profiling of Ovarian Granulosa Cell Tumors. Hormones and Cancer 2:3, 157-169
CrossRef31
B. A. Benayoun, A. B. Georges, D. L'Hote, N. Andersson, A. Dipietromaria, A.-L. Todeschini, S. Caburet, C. Bazin, M. Anttonen, R. A. Veitia. (2011) Transcription factor FOXL2 protects granulosa cells from stress and delays cell cycle: role of its regulation by the SIRT1 deacetylase. Human Molecular Genetics 20:9, 1673-1686
CrossRef32
Rachael Natrajan, Jorge S Reis-Filho. (2011) Next-generation sequencing applied to molecular diagnostics. Expert Review of Molecular Diagnostics 11:4, 425-444
CrossRef33
Michal R. Schweiger, Bernd Timmermann. 2011. Genomics and Cancer Risk Assessment. , 175-193.
CrossRef34
J-H Kim, S Yoon, M Park, H-O Park, J-J Ko, K Lee, J Bae. (2011) Differential apoptotic activities of wild-type FOXL2 and the adult-type granulosa cell tumor-associated mutant FOXL2 (C134W). Oncogene 30:14, 1653-1663
CrossRef35
Steve E Kalloger, Martin Köbel, Samuel Leung, Erika Mehl, Dongxia Gao, Krista M Marcon, Christine Chow, Blaise A Clarke, David G Huntsman, C Blake Gilks. (2011) Calculator for ovarian carcinoma subtype prediction. Modern Pathology 24:4, 512-521
CrossRef36
Alan Ashworth, Christopher J. Lord, Jorge S. Reis-Filho. (2011) Genetic Interactions in Cancer Progression and Treatment. Cell 145:1, 30-38
CrossRef37
Melissa K McConechy, Michael S Anglesio, Steve E Kalloger, Winnie Yang, Janine Senz, Christine Chow, Alireza Heravi-Moussavi, Gregg B Morin, Anne-Marie Mes-Masson, , Mark S Carey, Jessica N McAlpine, Janice S Kwon, Leah M Prentice, Niki Boyd, Sohrab P Shah, C. Blake Gilks, David G Huntsman. (2011) Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. The Journal of Pathology 223:5, 567-573
CrossRef38
Joseph T. Rabban, Anthony N. Karnezis, Charles J. Zaloudek. (2011) Non-epithelial ovarian tumours: a review of selected patterns that mimic epithelial tumours and other high-grade malignancies. Diagnostic Histopathology 17:4, 153-164
CrossRef39
M. R. Stratton. (2011) Exploring the Genomes of Cancer Cells: Progress and Promise. Science 331:6024, 1553-1558
CrossRef40
J.-Y. Fan, B. Han, J. Qiao, B.-L. Liu, Y.-R. Ji, S.-F. Ge, H.-D. Song, X.-Q. Fan. (2011) Functional study on a novel missense mutation of the transcription factor FOXL2 causes blepharophimosis-ptosis-epicanthus inversus syndrome (BPES). Mutagenesis 26:2, 283-289
CrossRef41
I. Millet, G. Rathat, H. Perrochia, D. Hoa, S. Mérigeaud, F. Curros-Doyon, P. Taourel. (2011) Aspect en imagerie des tumeurs de la granulosa de l’ovaire : à propos de trois cas. Journal de Radiologie 92:3, 236-242
CrossRef42
Barry S. Taylor, Marc Ladanyi. (2011) Clinical cancer genomics: how soon is now?. The Journal of Pathology 223:2, 319-327
CrossRef43
Brigitte L Thériault, Trevor G Shepherd. (2011) On the path to translation: Highlights from the 2010 Canadian Conference on Ovarian Cancer Research. Journal of Ovarian Research 4:1, 10
CrossRef44
Margaret C Cummings, Rachael Chambers, Peter T Simpson, Sunil R Lakhani. (2011) Molecular classification of breast cancer: is it time to pack up our microscopes?. Pathology 43:1, 1-8
CrossRef45
Stacey Jamieson, Ralf Butzow, Noora Andersson, Maria Alexiadis, Leila Unkila-Kallio, Markku Heikinheimo, Peter J Fuller, Mikko Anttonen. (2010) The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary. Modern Pathology 23:11, 1477-1485
CrossRef46
Annalisa Astolfi, Guido Biasco, Eduardo Bruera, Antonella Surbone. (2010) Progress in Genomic Technology: A New Challenge for the Palliative Medicine?. Journal of Pain and Symptom Management 40:5, e7-e9
CrossRef47
C. Fotopoulou, K. Savvatis, E-I. Braicu, V. Brink-Spalink, S. Darb-Esfahani, W. Lichtenegger, J. Sehouli. (2010) Adult granulosa cell tumors of the ovary: Tumor dissemination pattern at primary and recurrent situation, surgical outcome. Gynecologic Oncology 119:2, 285-290
CrossRef48
Birrer, Michael J., . (2010) The Origin of Ovarian Cancer — Is It Getting Clearer?. New England Journal of Medicine 363:16, 1574-1575
Full Text49
Wiegand, Kimberly C., Shah, Sohrab P., Al-Agha, Osama M., Zhao, Yongjun, Tse, Kane, Zeng, Thomas, Senz, Janine, McConechy, Melissa K., Anglesio, Michael S., Kalloger, Steve E., Yang, Winnie, Heravi-Moussavi, Alireza, Giuliany, Ryan, Chow, Christine, Fee, John, Zayed, Abdalnasser, Prentice, Leah, Melnyk, Nataliya, Turashvili, Gulisa, Delaney, Allen D., Madore, Jason, Yip, Stephen, McPherson, Andrew W., Ha, Gavin, Bell, Lynda, Fereday, Sian, Tam, Angela, Galletta, Laura, Tonin, Patricia N., Provencher, Diane, Miller, Dianne, Jones, Steven J.M., Moore, Richard A., Morin, Gregg B., Oloumi, Arusha, Boyd, Niki, Aparicio, Samuel A., Shih, Ie-Ming, Mes-Masson, Anne-Marie, Bowtell, David D., Hirst, Martin, Gilks, Blake, Marra, Marco A., Huntsman, David G., . (2010) ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas. New England Journal of Medicine 363:16, 1532-1543
Full Text50
Matthew Meyerson, Stacey Gabriel, Gad Getz. (2010) Advances in understanding cancer genomes through second-generation sequencing. Nature Reviews Genetics 11:10, 685-696
CrossRef51
K. Robison. (2010) Application of second-generation sequencing to cancer genomics. Briefings in Bioinformatics 11:5, 524-534
CrossRef52
Colin J.R. Stewart, Ai Rene Kee, Sukeerat Ruba. (2010) An Ovarian Tumor With Small Cell Pattern at Intraoperative Assessment. Pathology Case Reviews 15:5, 162-166
CrossRef53
Prue A. Cowin, Michael Anglesio, Dariush Etemadmoghadam, David D.L. Bowtell. (2010) Profiling the Cancer Genome. Annual Review of Genomics and Human Genetics 11:1, 133-159
CrossRef54
Andrew H. Fischer, Chengquan Zhao, Qing Kay Li, Karen S. Gustafson, Isam-Eldin Eltoum, Rosemary Tambouret, Barbara Benstein, Lynnette C. Savaloja, Peter Kulesza. (2010) The cytologic criteria of malignancy. Journal of Cellular Biochemistry 110:4, 795-811
CrossRef55
Puliyath GEETHA, M. Krishnan NAIR. (2010) Granulosa cell tumours of the ovary. Australian and New Zealand Journal of Obstetrics and Gynaecology 50:3, 216-220
CrossRef56
Britta Weigelt, Felipe C. Geyer, Jorge S. Reis-Filho. (2010) Histological types of breast cancer: How special are they?. Molecular Oncology 4:3, 192-208
CrossRef57
Min Sung Kim, Soo Young Hur, Nam Jin Yoo, Sug Hyung Lee. (2010) Mutational analysis of FOXL2 codon 134 in granulosa cell tumour of ovary and other human cancers. The Journal of Pathology 221:2, 147-152
CrossRef58
E. Despierre, D. Lambrechts, P. Neven, F. Amant, S. Lambrechts, I. Vergote. (2010) The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. Gynecologic Oncology 117:2, 358-365
CrossRef59
Thomas J. Hudson (Chairperson), Warwick Anderson, Axel Aretz, Anna D. Barker, Cindy Bell, Rosa R. Bernabé, M. K. Bhan, Fabien Calvo, Iiro Eerola, Daniela S. Gerhard, Alan Guttmacher, Mark Guyer, Fiona M. Hemsley, Jennifer L. Jennings, David Kerr, Peter Klatt, Patrik Kolar, Jun Kusuda, David P. Lane, Frank Laplace, Youyong Lu, Gerd Nettekoven, Brad Ozenberger, Jane Peterson, T.S. Rao, Jacques Remacle, Alan J. Schafer, Tatsuhiro Shibata, Michael R. Stratton, Joseph G. Vockley, Koichi Watanabe, Huanming Yang, Matthew M. F. Yuen, Bartha M. Knoppers (Leader), Martin Bobrow, Anne Cambon-Thomsen, Lynn G. Dressler, Stephanie O. M. Dyke, Yann Joly, Kazuto Kato, Karen L. Kennedy, Pilar Nicolás, Michael J. Parker, Emmanuelle Rial-Sebbag, Carlos M. Romeo-Casabona, Kenna M. Shaw, Susan Wallace, Georgia L. Wiesner, Nikolajs Zeps, Peter Lichter (Leader), Andrew V. Biankin, Christian Chabannon, Lynda Chin, Bruno Clément, Enrique de Alava, Françoise Degos, Martin L. Ferguson, Peter Geary, D. Neil Hayes, Thomas J. Hudson, Amber L. Johns, Arek Kasprzyk, Hidewaki Nakagawa, Robert Penny, Miguel A. Piris, Rajiv Sarin, Aldo Scarpa, Tatsuhiro Shibata, Marc van de Vijver, P. Andrew Futreal (Leader), Hiroyuki Aburatani, Mónica Bayés, David D.L. Bowtell, Peter J. Campbell, Xavier Estivill, Daniela S. Gerhard, Sean M. Grimmond, Ivo Gut, Martin Hirst, Carlos López-Otín, Partha Majumder, Marco Marra, John D. McPherson, Hidewaki Nakagawa, Zemin Ning, Xose S. Puente, Yijun Ruan, Tatsuhiro Shibata, Michael R. Stratton, Hendrik G. Stunnenberg, Harold Swerdlow, Victor E. Velculescu, Richard K. Wilson, Hong H. Xue, Liu Yang, Paul T. Spellman (Leader), Gary D. Bader, Paul C. Boutros, Peter J. Campbell, Paul Flicek, Gad Getz, Roderic Guigó, Guangwu Guo, David Haussler, Simon Heath, Tim J. Hubbard, Tao Jiang, Steven M. Jones, Qibin Li, Nuria López-Bigas, Ruibang Luo, Lakshmi Muthuswamy, B. F. Francis Ouellette, John V. Pearson, Xose S. Puente, Victor Quesada, Benjamin J. Raphael, Chris Sander, Tatsuhiro Shibata, Terence P. Speed, Lincoln D. Stein, Joshua M. Stuart, Jon W. Teague, Yasushi Totoki, Tatsuhiko Tsunoda, Alfonso Valencia, David A. Wheeler, Honglong Wu, Shancen Zhao, Guangyu Zhou, Lincoln D. Stein (Leader), Roderic Guigó, Tim J. Hubbard, Yann Joly, Steven M. Jones, Arek Kasprzyk, Mark Lathrop, Nuria López-Bigas, B. F. Francis Ouellette, Paul T. Spellman, Jon W. Teague, Gilles Thomas, Alfonso Valencia, Teruhiko Yoshida, Karen L. Kennedy (Leader), Myles Axton, Stephanie O. M. Dyke, P. Andrew Futreal, Daniela S. Gerhard, Chris Gunter, Mark Guyer, Thomas J. Hudson, John D. McPherson, Linda J. Miller, Brad Ozenberger, Kenna M. Shaw, Arek Kasprzyk (Leader), Lincoln D. Stein (Leader), Junjun Zhang, Syed A. Haider, Jianxin Wang, Christina K. Yung, Anthony Cross, Yong Liang, Saravanamuttu Gnaneshan, Jonathan Guberman, Jack Hsu, Martin Bobrow (Leader), Don R. C. Chalmers, Karl W. Hasel, Yann Joly, Terry S. H. Kaan, Karen L. Kennedy, Bartha M. Knoppers, William W. Lowrance, Tohru Masui, Pilar Nicolás, Emmanuelle Rial-Sebbag, Laura Lyman Rodriguez, Catherine Vergely, Teruhiko Yoshida, Sean M. Grimmond (Leader), Andrew V. Biankin, David D. L. Bowtell, Nicole Cloonan, Anna deFazio, James R. Eshleman, Dariush Etemadmoghadam, Brooke A. Gardiner, James G. Kench, Aldo Scarpa, Robert L. Sutherland, Margaret A. Tempero, Nicola J. Waddell, Peter J. Wilson, John D. McPherson (Leader), Steve Gallinger, Ming-Sound Tsao, Patricia A. Shaw, Gloria M. Petersen, Debabrata Mukhopadhyay, Lynda Chin, Ronald A. DePinho, Sarah Thayer, Lakshmi Muthuswamy, Kamran Shazand, Timothy Beck, Michelle Sam, Lee Timms, Vanessa Ballin, Youyong Lu (Leader), Jiafu Ji, Xiuqing Zhang, Feng Chen, Xueda Hu, Guangyu Zhou, Qi Yang, Geng Tian, Lianhai Zhang, Xiaofang Xing, Xianghong Li, Zhenggang Zhu, Yingyan Yu, Jun Yu, Huanming Yang, Mark Lathrop (Leader), Jörg Tost, Paul Brennan, Ivana Holcatova, David Zaridze, Alvis Brazma, Lars Egevad, Egor Prokhortchouk, Rosamonde Elizabeth Banks, Mathias Uhlén, Anne Cambon-Thomsen, Juris Viksna, Fredrik Ponten, Konstantin Skryabin, Michael R. Stratton (Leader), P. Andrew Futreal, Ewan Birney, Ake Borg, Anne-Lise Børresen-Dale, Carlos Caldas, John A. Foekens, Sancha Martin, Jorge S. Reis-Filho, Andrea L. Richardson, Christos Sotiriou, Hendrik G. Stunnenberg, Gilles Thomas, Marc van de Vijver, Laura van’t Veer, Fabien Calvo (Leader), Daniel Birnbaum, Hélène Blanche, Pascal Boucher, Sandrine Boyault, Christian Chabannon, Ivo Gut, Jocelyne D. Masson-Jacquemier, Mark Lathrop, Iris Pauporté, Xavier Pivot, Anne Vincent-Salomon, Eric Tabone, Charles Theillet, Gilles Thomas, Jörg Tost, Isabelle Treilleux, Fabien Calvo (Leader), Paulette Bioulac-Sage, Bruno Clément, Thomas Decaens, Françoise Degos, Dominique Franco, Ivo Gut, Marta Gut, Simon Heath, Mark Lathrop, Didier Samuel, Gilles Thomas, Jessica Zucman-Rossi, Peter Lichter (Leader), Roland Eils (Leader), Benedikt Brors, Jan O. Korbel, Andrey Korshunov, Pablo Landgraf, Hans Lehrach, Stefan Pfister, Bernhard Radlwimmer, Guido Reifenberger, Michael D. Taylor, Christof von Kalle, Partha P. Majumder (Leader), Rajiv Sarin, T. S. Rao, M. K. Bhan, Aldo Scarpa (Leader), Paolo Pederzoli, Rita T. Lawlor, Massimo Delledonne, Alberto Bardelli, Andrew V. Biankin, Sean M. Grimmond, Thomas Gress, David Klimstra, Giuseppe Zamboni, Tatsuhiro Shibata (Leader), Yusuke Nakamura, Hidewaki Nakagawa, Jun Kusuda, Tatsuhiko Tsunoda, Satoru Miyano, Hiroyuki Aburatani, Kazuto Kato, Akihiro Fujimoto, Teruhiko Yoshida, Elias Campo (Leader), Carlos López-Otín, Xavier Estivill, Roderic Guigó, Silvia de Sanjosé, Miguel A. Piris, Emili Montserrat, Marcos González-Díaz, Xose S. Puente, Pedro Jares, Alfonso Valencia, Heinz Himmelbaue, Victor Quesada, Silvia Bea, Michael R. Stratton (Leader), P. Andrew Futreal, Peter J. Campbell, Anne Vincent-Salomon, Andrea L. Richardson, Jorge S. Reis-Filho, Marc van de Vijver, Gilles Thomas, Jocelyne D. Masson-Jacquemier, Samuel Aparicio, Ake Borg, Anne-Lise Børresen-Dale, Carlos Caldas, John A. Foekens, Hendrik G. Stunnenberg, Laura van’t Veer, Douglas F. Easton, Paul T. Spellman, Sancha Martin, Anna D. Barker, Lynda Chin, Francis S. Collins, Carolyn C. Compton, Martin L. Ferguson, Daniela S. Gerhard, Gad Getz, Chris Gunter, Alan Guttmacher, Mark Guyer, D. Neil Hayes, Eric S. Lander, Brad Ozenberger, Robert Penny, Jane Peterson, Chris Sander, Kenna M. Shaw, Terence P. Speed, Paul T. Spellman, Joseph G. Vockley, David A. Wheeler, Richard K. Wilson, Thomas J. Hudson (Chairperson), Lynda Chin, Bartha M. Knoppers, Eric S. Lander, Peter Lichter, Lincoln D. Stein, Michael R. Stratton, Warwick Anderson, Anna D. Barker, Cindy Bell, Martin Bobrow, Wylie Burke, Francis S. Collins, Carolyn C. Compton, Ronald A. DePinho, Douglas F. Easton, P. Andrew Futreal, Daniela S. Gerhard, Anthony R. Green, Mark Guyer, Stanley R. Hamilton, Tim J. Hubbard, Olli P. Kallioniemi, Karen L. Kennedy, Timothy J. Ley, Edison T. Liu, Youyong Lu, Partha Majumder, Marco Marra, Brad Ozenberger, Jane Peterson, Alan J. Schafer, Paul T. Spellman, Hendrik G. Stunnenberg, Brandon J. Wainwright, Richard K. Wilson, Huanming Yang. (2010) International network of cancer genome projects. Nature 464:7291, 993-998
CrossRef60
JoAnne S. Richards, Stephanie A. Pangas. (2010) The ovary: basic biology and clinical implications. Journal of Clinical Investigation 120:4, 963-972
CrossRef61
R. Goya, M. G.F. Sun, R. D. Morin, G. Leung, G. Ha, K. C. Wiegand, J. Senz, A. Crisan, M. A. Marra, M. Hirst, D. Huntsman, K. P. Murphy, S. Aparicio, S. P. Shah. (2010) SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors. Bioinformatics 26:6, 730-736
CrossRef62
Raj Chari, Kelsie L. Thu, Ian M. Wilson, William W. Lockwood, Kim M. Lonergan, Bradley P. Coe, Chad A. Malloff, Adi F. Gazdar, Stephen Lam, Cathie Garnis, Calum E. MacAulay, Carlos E. Alvarez, Wan L. Lam. (2010) Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer. Cancer and Metastasis Reviews 29:1, 73-93
CrossRef63
Taeeun Kim, Chang Ohk Sung, Sang Yong Song, Duk-Soo Bae, Yoon-La Choi. (2010) FOXL2 mutation in granulosa-cell tumours of the ovary. Histopathology 56:3, 408-410
CrossRef64
C. Blake Gilks. (2010) Molecular Abnormalities in Ovarian Cancer Subtypes Other than High-Grade Serous Carcinoma. Journal of Oncology 2010, 1-7
CrossRef65
Matthew J Walter, Timothy A Graubert, John F DiPersio, Elaine R Mardis, Richard K Wilson, Timothy J Ley. (2009) Next-generation sequencing of cancer genomes: back to the future. Personalized Medicine 6:6, 653-662
CrossRef66
Shendure, Jay, Stewart, Colin J., . (2009) Cancer Genomes on a Shoestring Budget. New England Journal of Medicine 360:26, 2781-2783
Full Text67
Daphne W Bell. (2009) Our changing view of the genomic landscape of cancer. The Journal of Pathologyn/a-n/a
CrossRef68
Samuel AJR Aparicio, David G Huntsman. (2009) Does massively parallel DNA resequencing signify the end of histopathology as we know it?. The Journal of Pathologyn/a-n/a
CrossRef
- Glossary
Glossary
-
Bit:
A measure of the purity of the distribution of alleles at each nucleotide position, with 2 representing a homozygous position.
-
Grantham distance:
A measure of amino acid dissimilarity developed by Grantham in 1974 on the basis of composition, polarity, and molecular volume of amino acids.
-
Paired-end sequencing:
Sequencing of fragmented and size-selected complementary DNA from both ends, resulting in two short sequences with an unsequenced insertion between the sequences.
-
Restriction-fragment–length polymorphism:
A variation in the DNA sequence that can be determined by an assay that takes advantage of a restriction site that is either introduced or removed by a polymorphism; the assay verifies the presence of the polymorphism with the use of restriction-enzyme digestion, followed by gel electrophoresis.
-
RNA sequencing:
A standard term for whole-transcriptome sequencing with the use of high-throughput parallel processing technology to sequence randomly fragmented, size-selected DNA (see the Supplementary Appendix for details).
-
Sequencing read:
A short string of decoded nucleotides that is obtained from a single fragment of DNA or RNA. Millions of reads are compiled through analytic software to determine allelic frequency at each position.
-
Sex cord–stromal tumor:
Any tumor that is derived from ovarian stroma, including sex cords, forerunners of the endocrine apparatus of the postnatal ovary.
-
TaqMan:
A rapid fluorophore-based real-time polymerase-chain-reaction assay that uses specific primers and labeled probes to detect sequence variants.
-
Transcriptome:
The set of all messenger-RNA transcripts that are present in a cell or population of cells.
-
